查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591895

人類乳突病毒檢測市場：按產品、最終用戶、應用分類 - 2025-2030 年全球預測

Human Papillomavirus Testing Market by Product (Consumables, Systems), End-User (Clinical Diagnostic Laboratories, Hospitals, Physicians' Office Laboratories), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，人類乳突病毒檢測市值為11.1億美元，預計到2024年將達到12.6億美元，複合年成長率為13.58%，到2030年將達到27.1億美元。

人類乳突病毒 (HPV) 檢測是早期發現和預防子宮頸癌和其他 HPV 相關疾病的重要組成部分。在市場上，HPV 檢測包括分子檢測、基於 DNA 的檢測和血清學檢測，主要用於醫院、診斷實驗室和癌症研究中心等醫療機構。 HPV 感染盛行率的增加和子宮頸癌病例的相關增加推動了對 HPV 檢測的需求，作為主要篩檢方法和異常子宮頸抹片檢查後的後續檢測，因此強調了其重要應用。最終使用者包括醫療保健提供者、診斷中心和尋求早期準確診斷的患者。市場成長受到技術創新進步的顯著影響，這些技術創新使 HPV 檢測更加準確、價格實惠且易於使用。將人工智慧和機器學習整合到診斷工具中，有可能實現更複雜的分析和明智的決策。然而，某些人群的認知度低、保險範圍有限以及高級診斷測試的高價格構成了巨大的限制和挑戰。此外，各地區不同的監管標準進一步加劇了市場擴張的複雜性。為了抓住新的機遇，相關人員將投資於旨在提高檢測敏感性和特異性的研究，以及健康教育計畫的策略，以提高人們對人類乳突病毒(HPV)疫苗接種和檢測的認知和接受度。透過專注於開發可在資源匱乏的環境中部署的具有成本效益的模型，我們可以擴大我們的市場範圍。市場情勢本質上是競爭性的，迫使企業在應對監管環境的同時不斷創新。創新成熟的領域包括開發將 HPV 檢測與其他 STI 診斷相結合的綜合檢測平台，以及開發在提供便利且不影響可靠性的情況下提供便利的家庭檢測解決方案。此外，利用公私夥伴關係合作可以加速市場的進步和採用。

主要市場統計
基準年[2023] 11.1億美元
預測年份 [2024] 12.6億美元
預測年份 [2030] 27.1億美元
複合年成長率（%） 13.58%

市場動態：快速發展的人類乳突病毒檢測市場的關鍵市場洞察

供需的動態交互作用正在改變人類乳突病毒檢測市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 子宮頸癌患者增加和人口老化
    • 提高對子宮頸癌篩檢計畫的認知
    • 政府措施和資金
  • 市場限制因素
    • 男性無法進行 HPV 檢測
  • 市場機會
    • HPV初步篩檢簡介
    • HPV聯合檢測需求增加
  • 市場挑戰
    • 贖回場景不明確

波特五力：駕馭人類乳突病毒檢測市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對人類乳突病毒檢測市場的影響

外部宏觀環境因素在塑造人類乳突病毒檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解人類乳突病毒檢測市場的競爭狀況

對人類乳突病毒測試市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣人類乳突病毒檢測市場供應商的績效評估

FPNV定位矩陣是評估人類乳突病毒檢測市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了人類乳突病毒檢測市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對人類乳突病毒檢測市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 子宮頸癌患者數量不斷增加，人口老化加劇
      • 提高對子宮頸癌篩檢計畫的認知
      • 政府措施和資金
    • 抑制因素
      • 不提供男性 HPV 檢測
    • 機會
      • HPV初步篩檢簡介
      • 對 HPV 同時檢測的需求增加
    • 任務
      • 不確定的贖回場景
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章人類乳突病毒檢測市場：依產品

  • 消耗品
  • 系統

第7章 人類乳突病毒檢測市場：依最終用戶分類

  • 臨床診斷實驗室
  • 醫院
  • 醫生辦公室檢查室

第8章人類乳突病毒檢測市場：依應用分類

  • 生物感測器
  • 染色體分析
  • 流式細胞技術
  • 免疫檢測
  • 微陣列
  • 分子診斷
  • 單株和多株抗體

第9章美洲人類乳突病毒檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太人類乳突病毒檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲人類乳突病毒檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Arbor Vita Corporation
  • Becton, Dickinson and Company
  • Cepheid
  • Dalrada Corporation
  • Everlywell Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio Diagnostics
  • IncellDx
  • Neodiagnostix
  • Nurx Inc.
  • OralDNA Labs
  • QIAGEN NV
  • Quest Diagnostics
  • Sansure Biotech Inc.
Product Code: MRR-43127F7278E2

The Human Papillomavirus Testing Market was valued at USD 1.11 billion in 2023, expected to reach USD 1.26 billion in 2024, and is projected to grow at a CAGR of 13.58%, to USD 2.71 billion by 2030.

Human Papillomavirus (HPV) testing is a vital component in the early detection and prevention of cervical cancer and other HPV-related conditions. Within the scope of the market, HPV testing encompasses molecular assays, DNA-based tests, and serological testing used primarily in healthcare settings such as hospitals, diagnostic laboratories, and cancer research centers. The necessity for HPV testing is driven by the increasing prevalence of HPV infections and the consequent rise in cervical cancer cases, emphasizing its critical application as both a primary screening method and a follow-up test post-abnormal Pap smear results. End-users broadly include healthcare providers, diagnostic centers, and patients looking for early and accurate diagnosis. Market growth is significantly influenced by advancing technological innovations which are making HPV tests more accurate, affordable, and accessible. Integration of artificial intelligence and machine learning in diagnostic tools holds promising potential for more sophisticated analysis and informed decision-making. However, the lack of awareness in certain demographics, limited insurance coverage, and high cost of advanced diagnostic tests pose substantial limitations and challenges. In addition, variations in regulatory standards across regions further complicate market expansion. To seize emerging opportunities, stakeholders should invest in research aimed at enhancing test sensitivity and specificity, and in strategies for health education programs to expand awareness and acceptance of HPV vaccination and testing. Focus on developing cost-efficient models that can be deployed in low-resource settings would broaden market reach. The market's nature is inherently competitive, with constant pressure to innovate while navigating regulatory landscapes. Areas ripe for innovation include developing integrated testing platforms that combine HPV detection with other STI diagnostics, and creating home-based testing solutions that provide convenience without compromising reliability. Leveraging partnerships across the private and public sectors could also accelerate market advancement and penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 1.11 billion
Estimated Year [2024] USD 1.26 billion
Forecast Year [2030] USD 2.71 billion
CAGR (%) 13.58%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Papillomavirus Testing Market

The Human Papillomavirus Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing number of cervical cancer cases and growing aging population
    • Growing awareness of cervical cancer screening programs
    • Government initiatives and funding
  • Market Restraints
    • Non-availability of HPV test for men
  • Market Opportunities
    • Introduction of HPV primary screening tests
    • Increasing Demand for HPV Co-testing
  • Market Challenges
    • Uncertain reimbursement scenario

Porter's Five Forces: A Strategic Tool for Navigating the Human Papillomavirus Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Papillomavirus Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Papillomavirus Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Papillomavirus Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Papillomavirus Testing Market

A detailed market share analysis in the Human Papillomavirus Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Papillomavirus Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Papillomavirus Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Papillomavirus Testing Market

A strategic analysis of the Human Papillomavirus Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Papillomavirus Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cepheid, Dalrada Corporation, Everlywell Inc., F. Hoffmann-La Roche AG, Fujirebio Diagnostics, IncellDx, Neodiagnostix, Nurx Inc., OralDNA Labs, QIAGEN N.V., Quest Diagnostics, and Sansure Biotech Inc..

Market Segmentation & Coverage

This research report categorizes the Human Papillomavirus Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables and Systems.
  • Based on End-User, market is studied across Clinical Diagnostic Laboratories, Hospitals, and Physicians' Office Laboratories.
  • Based on Application, market is studied across Biosensors, Chromosome Analysis, Flow Cytometry, Immunoassays, Microarrays, Molecular Diagnostics, and Monoclonal & Polyclonal Antibodies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing number of cervical cancer cases and growing aging population
      • 5.1.1.2. Growing awareness of cervical cancer screening programs
      • 5.1.1.3. Government initiatives and funding
    • 5.1.2. Restraints
      • 5.1.2.1. Non-availability of HPV test for men
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of HPV primary screening tests
      • 5.1.3.2. Increasing Demand for HPV Co-testing
    • 5.1.4. Challenges
      • 5.1.4.1. Uncertain reimbursement scenario
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Papillomavirus Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Systems

7. Human Papillomavirus Testing Market, by End-User

  • 7.1. Introduction
  • 7.2. Clinical Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Physicians' Office Laboratories

8. Human Papillomavirus Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Biosensors
  • 8.3. Chromosome Analysis
  • 8.4. Flow Cytometry
  • 8.5. Immunoassays
  • 8.6. Microarrays
  • 8.7. Molecular Diagnostics
  • 8.8. Monoclonal & Polyclonal Antibodies

9. Americas Human Papillomavirus Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Papillomavirus Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Papillomavirus Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Arbor Vita Corporation
  • 3. Becton, Dickinson and Company
  • 4. Cepheid
  • 5. Dalrada Corporation
  • 6. Everlywell Inc.
  • 7. F. Hoffmann-La Roche AG
  • 8. Fujirebio Diagnostics
  • 9. IncellDx
  • 10. Neodiagnostix
  • 11. Nurx Inc.
  • 12. OralDNA Labs
  • 13. QIAGEN N.V.
  • 14. Quest Diagnostics
  • 15. Sansure Biotech Inc.

LIST OF FIGURES

  • FIGURE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HUMAN PAPILLOMAVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HUMAN PAPILLOMAVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN PAPILLOMAVIRUS TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PHYSICIANS' OFFICE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CHROMOSOME ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MONOCLONAL & POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. HUMAN PAPILLOMAVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. HUMAN PAPILLOMAVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2023